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 Introduction 
 The breast cancer resistance protein (BCRP/ABCG2) 
is a half-transporter that belongs to the G subfamily of 
ATP-binding cassette (ABC) transporters. Similar to P-
glycoprotein, the product of the MDR1/ABCB1 gene, 
BCRP was detected and cloned from multi-drug resistant 
tumor cells [Doyle et al., 1998; Miyake et al., 1999]. Both 
efflux transporters are highly expressed in organs that 
play a protective role against toxic substances such as the 
intestine, the kidney, the liver, the blood brain barrier, 
and the placenta [Maliepaard et al., 2001]. In human je-
junum, BCRP is even more expressed than P-glycopro-
tein [Taipalensuu et al., 2001]. BCRP mediates the trans-
location of various drugs like methotrexate, mitoxan-
trone, anthracyclines, SN-38, and topotecan [Doyle et al., 
1998; Volk and Schneider, 2003; Schellens et al., 2000]. It 
has further an essential role in extruding metabolites 
such as glucuronide and sulfate conjugates formed in en-
terocytes into the intestinal lumen [Adachi et al., 2005]. 
Moreover, BCRP protects the body from toxic constitu-
ents of food such as the carcinogen PhIP (2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine) and the chlo-
rophyll-derived phototoxin pheophorbide-a [van Her-
waarden et al., 2003; Jonker et al., 2002]. In summary, its 
localization in the apical membrane of intestinal cells and 
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 Abstract 
 Background/Aims: The expression of transporters involved 
in bile acid homeostasis is differentially regulated during ob-
structive cholestasis. Since the drug efflux transporter breast 
cancer resistance protein (BCRP) is known to transport bile 
acids, we investigated whether duodenal BCRP expression 
could be altered during cholestasis.  Methods: Using real-
time RT-PCR analysis we determined mRNA expression lev-
els in duodenal tissue of 19 cholestatic patients. Expression 
levels were compared to 14 healthy subjects. BCRP protein 
staining was determined in biopsies of 6 cholestatic and 6 
healthy subjects by immunohistochemistry.  Results: We 
found that in patients with obstructive cholestasis mean du-
odenal BCRP mRNA levels were significantly reduced to 53% 
and mean protein staining was reduced to 57%.  Conclu-
sions: BCRP, a transporter for bile acids and numerous drugs, 
appears to be down-regulated in the human duodenum 
during cholestasis. The clinical impact of these results has to 
be investigated in further studies. 
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its wide substrate specificity suggests that BCRP is an im-
portant transporter limiting the absorption of orally ad-
ministered drugs and ingested toxins. 
 Most members of the ABCG subfamily are involved in 
the translocation of endogenous compounds. ABCG1 is 
supposed to be a regulator of cholesterol and phospho-
lipid transport [Klucken et al., 2000], whereas the het-
erodimeric proteins ABCG5/ABCG8 promote biliary ex-
cretion and limit intestinal absorption of neutral sterols 
[Yu et al., 2002]. It was shown that BCRP can also trans-
port endogenous substrates such as sulphated steroids 
[Imai et al., 2005; Suzuki et al., 2003] and primary bile 
acids [Janvilisri et al., 2005]. The precise physiological 
role of BCRP remains, however, to be defined.
 The fact that BCRP is capable of transporting bile ac-
ids may indicate that this transporter is involved in bile 
acid homeostasis. As an efflux pump, it could protect the 
enterocytes from potential toxic bile acid concentrations. 
During cholestasis, in which the enterohepatic circula-
tion is disrupted, an adaptive regulation of transporters 
for bile acids, bilirubin and cholesterol occurs [Kamisako 
and Ogawa, 2005; Tanaka et al., 2002; Zollner et al., 2003; 
Denk et al., 2004]. These changes take place in the liver, 
the kidney, as well as in the intestine. We have recently 
shown that the responsible gene for bile acid reuptake in 
the intestine, the apical sodium dependent bile acid trans-
porter (ASBT), is down-regulated in cholestatic patients 
[Hruz et al., 2006].
 Here we have analyzed the duodenal expression of 
BCRP in patients with obstructive cholestasis. The dis-
ease is associated with elevated bile acid levels in serum, 
a lack of bile acids in the intestinal lumen, and increase 
in proinflammatory cytokines [Plebani et al., 1999]. We 
hypothesized that BCRP, as a potential bile acid trans-
porter, could show an altered gene expression during ob-
structive cholestasis. Indeed, we can show that choles-
tatic patients exhibit decreased BCRP expression in the 
intestine compared to healthy subjects. Further studies 
are necessary to characterize the impact of these results 
on the pharmacokinetics of drugs and the exposure to 
dietary toxins that are BCRP substrates.
 Materials and Methods 
 Patients 
 Fourteen healthy subjects (7 females, 7 males) and 19 choles-
tatic patients (10 females, 9 males) were enrolled in the study after 
giving informed consent. The group of control subjects had a 
mean age of 59.8 (43–75) years and cholestatic patients 67.5 (41–
85) years. Biochemical parameters of both groups are displayed 
in  table 1 . The control subjects had an indication for a gastroin-
testinal tract endoscopy within a cancer-screening program, 
whereas patients with obstructive cholestasis had an interven-
tional endoscopic retrograde cholangiopancreatography (ERCP). 
Within the cholestatic group, nine patients had obstructive tu-
mors (3 carcinoma of the pancreatic head, 4 cholangiocarcinoma 
(Klatskin tumor) and two metastatic diseases). 10 patients had 
benign diseases (8 patients with choledocholithiasis and 2 pa-
tients with benign stenosis of the common bile duct). Patients had 
no clinical signs of cholangitis. Shortly before endoscopic inter-
vention patients undergoing ERCP received 4 g piperacillin/0.5 g 
tazobactam. Patients taking medication which is known to induce 
drug transporters were excluded from the study.
 Obstructive jaundice was defined on the basis of chemical pa-
rameters (bilirubin,   -glutamyltransferase, and alkaline phos-
phatase) and on imaging procedures (ultrasound and ERCP) 
demonstrating a dilated bile duct system. All control patients had 
normal values of the above mentioned parameters. During endos-
copy four biopsy specimens were obtained from the distal part of 
the duodenum. Biopsies were immediately stored at –70  °  C until 
further processing. The study was approved by the State Ethical 
Committee of Basel (Ethische Kommission beider Basel, EKBB) 
and recorded in the clinical trial register of the United States Na-
tional Library of Medicine (ID: NTC00295360).
Parameter Controls Patients with 
cholestasis
p value
Bilirubin [5–26 mol/l] 11.5 (5.0–17.0) 182.5 (42–640) <0.001
ALAT [10–37 U/l] 26.0 (10–35) 144 (10–633) <0.003
ASAT [11–36 U/l] 24.5 (10–38) 70.5 (10–361) <0.002
-GT [11–66 U/l] 59.0 (45–68) 449.5 (74–1,510) <0.001
AP [43–106 U/l] 71.0 (44–84) 257.0 (100–1,855) <0.01
Total cholesterol [3–5.2 mmol/l] 5.9 (3.9–6.6) 5.5 (2.7–10.8) NS
Bile acids [<10 mol/l] 1.7 (0.5–3.2) 87.7 (20.5–431.3) <0.001
Values are medians (range). The normal range is in square brackets. NS = Statisti-
cally not significant.
Table 1. Biochemical parameters 
measured in control subjects and in 
patients with cholestasis
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 Real-Time RT-PCR Analysis (TaqMan) 
 Total RNA was isolated from 2 biopsies from each subject. 
RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH, 
Hilden, Germany) following the instructions provided by the 
manufacturer. RNA was quantified with a GeneQuant photom-
eter (Pharmacia, Uppsala, Sweden). After DNase I digestion (Gib-
co, Life Technologies, Basel Switzerland) 1.5   g of total RNA was 
reverse-transcribed by Superscript (Gibco Life Technologies) ac-
cording to the manufacturer’s protocol using random hexamers 
as primers.
 TaqMan analysis was carried out on a 7900HT Sequence De-
tection System (Applied Biosystems, Rotkreuz, Switzerland) as 
previously described in recent papers of our group [Hruz et al., 
2006; Zimmermann et al., 2005; Gutmann et al., 2005]. In brief, 
the standards we used for mRNA quantification were obtained by 
classical PCR using duodenal cDNA as a template. Primers for 
generating the standards and primers/probes for TaqMan analy-
sis were designed according to the guidelines of Applied Biosys-
tems with the help of the Primer Express 2.0 software (corre-
sponding sequences are displayed in  table 2 ). All samples were 
run in triplicates and were quantified using a standard curve. Not 
reverse-transcribed RNA served as a negative control. For each 
sample the transcript numbers of BCRP and of villin were deter-
mined. By calculating the ratio BCRP/villin, the mRNA expres-
sion was normalized. This approach has been established to ac-
count for variations in the enterocyte content of biopsies [Tai-
palensuu et al., 2001; Lown et al., 1997].
 Immunohistochemistry 
 Human duodenal tissue fragments were mounted in OCT 
compound (Sakura Finetek, Zooterwoude, The Netherlands), 
snap frozen in liquid nitrogen and stored at –70  °  C. Frozen sec-
tions (5   m) were then air dried overnight and a periodate-lysine 
paraformaldehyde solution (3%) was used for postfixation. Then 
the sections were washed with washing solution (TBS/NaCl, 
Tween 0.05%) and incubated with normal horse serum for 30 min 
at room temperature as blocking solution. The tissue sections 
were incubated with a 1:  40 dilution of the BCRP monoclonal an-
tibody BXP-21 (Alexis Biochemicals, Lausen, Switzerland) over-
night at 4  °  C. Samples were washed three times with washing 
solution and incubated with the horse antimouse IgG secondary 
antibody for 30 min at room temperature. After three washes 
with the washing solution, a perhydral solution (H 2 O 2  (0.3%), 
sodium azide (0.1%) in PBS) was used to destroy the endogenous 
peroxidase activity. The staining was performed with the avidin/
biotinylated enzyme complex (ABC method) according to the 
manufacturer’s instructions (Vectastain, Elite kit, Vector Labo-
ratories, Burlingame,  Calif., USA). For detection 3-amino-9-eth-
ylcarbazole (AEC), which forms a red end product, was used 
(Biogenex, San Ramon, Calif., USA). Sections, which served as 
negative controls, were treated equally except that they were not 
incubated with the primary antibody. Semiquantitative analysis 
of BCRP staining in biopsies of 6 control subjects and 6 choles-
tatic patients was done by a trained pathologist by assessing pro-
tein staining on blinded specimens. Expression levels were rated 
as follows: 0 = no expression, 1 = low, 2 = intermediate, 3 = high 
expression.
 Bile Acid and Bilirubin Plasma Concentrations 
 Blood samples from all subjects were obtained shortly before 
endoscopic procedure. Fasting plasma levels of bile acids were de-
termined as described previously by our group [Hruz et al., 2006] 
using the method of Stellaard et al. [1984]. Bilirubin plasma con-
centrations were measured by a modified Malloy-Evelyn method 
(BIL-T, Roche Diagnostics, Mannheim, Germany).
 Statistics 
 All values were expressed as means  8 SEM. Icteric patient’s 
BCRP expression was compared to that of healthy controls by 
analysis of variance (ANOVA). All comparisons were performed 
as two-sided comparisons using the SPSS for Windows software 
(version 14.0). Level of significance was p  ! 0.05.
 Results 
 BCRP mRNA Expression Is Down-Regulated during 
Cholestasis 
 Duodenal mRNA expression of BCRP and villin was 
analyzed in 14 healthy subjects and 19 patients with ob-
structive cholestasis. In cholestatic patients mean BCRP 
mRNA levels were reduced to 53.6% when compared to 
BCRP
PCR primer forward 5-TTTCAGCCGTGGAACTCTTT-3
PCR primer reverse 5-TGAGTCCTGGGCAGAAGTTT-3
TaqMan primer forward 5-CAGGTCTGTTGGTCAATCTCACA-3
TaqMan probe 5-CCATTGCATCTTGGCTGTCATGGCTT-3
TaqMan primer reverse 5-TCCATATCGTGGAATGCTGAAG-3
Villin
PCR primer forward 5-AGAAAGCCAATGAGCAGGAGAA-3
PCR primer reverse 5-ATGGATGTGGCATCGAACTTC-3
TaqMan primer forward 5-CATGAGCCATGCGCTGAAC-3
TaqMan probe 5-TCATCAAAGCCAAGCAGTACCCACCAAG-3
TaqMan primer reverse 5-TCATTCTGCACCTCCACCTGT-3
Table 2. Sequences of PCR primers used 
for generating the cDNA standards and 
of TaqMan primers/probes used for 
real-time PCR
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healthy subjects. Relative expression (mean BCRP/villin 
 8 SEM) was 0.51 ( 8 0.03) in controls and 0.27 ( 8 0.02) 
in cholestatic patients (p  ! 0.001) ( fig. 1 a). Mean villin 
mRNA expression was not significantly different be-
tween the control and cholestatic groups (data not shown). 
 Figure 2 displays the individual BCRP mRNA expression 
in correlation to bile acid serum concentration ( fig. 2 a) 
and bilirubin serum concentration ( fig. 2 b). 
 Patients with cholestasis due to tumor or biliary stones 
did not differ in their BCRP expression: on average, this 
amounted to 0.26  8 0.038 (SEM), n = 9 and 0.28  8 
0.031, n = 10. This difference was not statistically signif-
icant.
 BCRP Protein Levels Are Decreased in Cholestatic 
Patients  
 BCRP protein expression was evaluated by immuno-
histochemistry in 6 control subjects and 6 patients with 
cholestasis. BCRP protein was expressed on the apical 
membrane of the duodenal epithelial cells. Representa-
tive pictures of duodenal tissues are displayed in  figure 
3 a (healthy subject) and  figure 3 b (cholestatic patient). 
Expression levels were rated as follows: 0 = no expression, 
1 = low, 2 = intermediate, 3 = high expression. In patients 
with obstructive cholestasis mean BCRP protein levels 
were reduced to 57.1% when compared to healthy sub-
jects. Protein expression (mean  8 SEM) was 2.91 ( 8 
0.08) in control subjects and 1.67 ( 8 0.38) in cholestatic 
patients (p  ! 0.005) ( fig. 1 b).
 Correlation of BCRP mRNA Expression with Age and 
Body Mass Index 
 Age was not significantly (p = 0.14; R 2  = –0.26) corre-
lated with BCRP mRNA expression. However, there was 
a statistically significant (p = 0.041) positive although 
weak (R 2  = 0.36) correlation body mass index with BCRP 
mRNA expression.
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 Fig. 2. Individual BCRP mRNA expression (BCRP/villin) in 13 
healthy subjects and 16 cholestatic patients. BCRP mRNA expres-
sion is shown in correlation to bile acid serum concentration. 
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 Fig. 1. Comparison of BCRP expression in 
healthy subjects versus cholestatic patients 
(mean  8 SEM).  a Expression of BCRP 
mRNA relative to villin (14 controls versus 
19 cholestatic patients).  b BCRP protein 
expression using immunohistochemical 
staining with semi-quantitative analysis
(6 controls vs. 6 cholestatic patients). 
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 Effect of Reconstitution of Bile Flow on BCRP mRNA 
Expression  
 In 4 patients, a follow-up gastroscopy could be per-
formed 10–40 weeks after reconstitution of bile flow (data 
not shown). A follow-up endoscopy was only performed 
when medically indicated. Two of the 4 patients received 
stents into the common bile duct due to a biliary stone, 1 
patient had a Whipple operation due to tumor of the pan-
creas head and one due to cholangiocarcinoma. 
 These patients showed normalized bile acid and bili-
rubin plasma levels at the time when duodenal follow-up 
biopsies were taken. In 3 patients the BCRP mRNA ex-
pression increased (1.44-, 1.71-, and 1.90-fold) when 
compared to the expression level of cholestasis. In one 
patient, the level did not change clinically significantly 
(1.05-fold increase). This patient suffered from choledo-
cholithiasis, had low initial bilirubin (65   mol/l) as well 
as bile acid (44.7   mol/l) plasma levels and was the pa-
tient with the shortest interval to follow-up endoscopy 
(10 weeks).
 Discussion 
 Our data demonstrate that during complete or near 
complete obstruction of the bile duct by a tumor or bili-
ary stone intestinal BCRP expression is down-regulated 
on the transcriptional level leading to reduced amount of 
BCRP protein. 
 At the moment, little is known about the transcrip-
tional regulation of this transporter. Only recently, an es-
trogen response element in the BCRP promotor was dis-
covered [Ee et al., 2004]. Tanaka et al. [2005] observed, 
however, a higher BCRP expression in the kidney and 
liver of male rats and male mice, respectively. Further-
more, it has been reported that estrogens down-regulate 
BCRP protein expression by posttranscriptional mecha-
nisms [Imai et al., 2005]. Recently, we have analyzed 
BCRP mRNA expression along the human gastrointesti-
nal tract of healthy subjects with respect to sex [Gutmann 
et al., 2005]. No sex-related differences were observed. 
The data of the present study again show no significant 
differences between women and men (data not shown). 
We infer from these data that sexual hormones have most 
probably no effect on the expression of BCRP in the hu-
man intestine.
 This is the first study demonstrating that the expres-
sion of BCRP is altered in the human intestine during 
disease. Our results are in conflict with another study, 
where no differences in duodenal BCRP protein levels 
were observed between icteric patients and healthy sub-
jects [Dietrich et al., 2004a]. The authors analyzed the 
expression of several ABC transporters including BCRP 
in the human intestine and found only MRP2 to be down-
 Fig. 3. Immunohistochemical staining of BCRP protein on the apical membrane of human duodenal epithelial 
cells using the BCRP antibody BXP-21.  a Clear staining of BCRP protein in a duodenal sample from a healthy 
subject.  b Reduced staining in a duodenal sample of a patient with obstructive cholestasis. Both pictures are at 
200-fold magnification. 
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regulated. A possible explanation for this discrepancy 
could be different durations and/or severity of cholestasis 
between the two patient groups. Although the duration 
of cholestasis is not known in both studies, the patients 
in our study exhibited a higher mean level of bilirubin 
(235 vs. 174   mol/l), which could indicate a higher sever-
ity of cholestasis. 
 During cholestasis, the expression of bile acid and bil-
irubin transporters such as the ABC-transporters MRP2, 
MRP3, MRP4, and organic anion transporting polypep-
tides (OATPs) is significantly changed [Tanaka et al., 
2002; Denk et al., 2004; Dietrich et al., 2004a; Wagner et 
al., 2003]. Alterations in transporter expression do not 
only occur in the liver but also in remote organs such as 
the kidney and intestine. The systemic mediators that 
regulate these events during cholestasis have not been 
fully discovered. Proinflammatory cytokines, bile salts, 
or hormones have been suggested to control transporter 
gene expression [Trauner et al., 2005]. 
 IL-1  has been identified as the central mediator for 
the down-regulation of intestinal and hepatic MRP2
[Dietrich   et   al.,  2004a;  Denson  et  al.,  2002].  TNF-   and 
 IL-1   are responsible for the down-regulation of several 
other hepatobiliary transporters [Geier et al., 2003]. Cy-
tokines mediate these effects by reducing the binding ac-
tivity of nuclear receptors to the corresponding promot-
ers [Denson et al., 2002; Geier et al., 2003; Li and Klaas-
sen, 2004]. Bile acids, on the other hand, act through 
binding to their endogenous receptor farnesoid X recep-
tor (FXR), which induces the expression of small het-
erodimer partner (SHP) [Lu et al., 2000]. SHP in turn 
represses the expression of several genes involved in bile 
acid homeostasis [Jung and Kullak-Ublick, 2003; Popow-
ski et al., 2005]. PXR is a further transcription factor that 
can be activated by bile acids [Xie et al., 2001]. PXR acti-
vation leads to the induction of multiple detoxification 
pathways including transporters [Stedman et al., 2005]. 
Moreover, hormones like glucocorticoids can influence 
transporter expression, as they are able to transactivate 
the intestinal bile acid transporter ASBT via the gluco-
corticoid receptor [Jung et al., 2004]. However, until now, 
there are no indications that intestinal BCRP could also 
be regulated by the above-mentioned mechanisms, 
though members of the ABCG subfamily such as ABCG1 
and ABCG5/ABCG8 are repressed by bile acids via the 
FXR-SHP pathway in vitro [Freeman et al., 2004; Brendel 
et al., 2002]. This demonstrates that further investiga-
tions concerning BCRP regulation are required. 
 In the state of obstructive cholestasis, virtually no bile 
acids are present in the intestinal lumen. If BCRP medi-
ates the efflux of bile salts that entered the enterocyte 
from the lumen, a down-regulation of this transporter 
could reflect an adaptive regulation during cholestasis. 
On the other hand, as BCRP is a potent efflux pump for 
a variety of toxic compounds, a diminished expression 
could weaken the intestinal barrier and the excretory 
function of the gut. In this respect, Dietrich et al. [2004b] 
determined the elimination of the dietary carcinogen 
PhIP in bile duct ligated rats. They demonstrated that the 
excretion of this toxin was significantly reduced in paral-
lel with a decreased expression of MRP2 and BCRP in 
liver. Furthermore, tissue binding of reactive metabolites 
was increased in liver and colon. A reduced intestinal 
BCRP expression could substantially contribute to the 
accumulation of carcinogens in enterocytes. This in turn 
might partly explain the observation that patients with 
primary sclerosing cholangiitis, a chronic cholestatic dis-
ease, have a higher risk of developing colorectal carci-
noma [Broome et al., 1995]. However, many patients with 
primary sclerosing cholangiitis have an associated ulcer-
ative colitis, which per se represents a kind of precancer-
ous state [Smith and Loe, 1965].
 In conclusion, we showed that patients with obstruc-
tive cholestasis exhibit a decreased expression of BCRP 
on mRNA and protein level. A decreased expression of 
this efflux pump might increase the accumulation of 
food-derived carcinogens and influence the pharmacoki-
netics of various anticancer drugs. However, the reduced 
expression of a certain transport protein may not be pre-
dictive for the impaired intestinal extrusion of a certain 
substrate. To evaluate potential clinical implications of 
these findings, further studies are needed.
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